Annelieke H J Petrus1, Olaf M Dekkers2, Laurens F Tops3, Eva Timmer1, Robert J M Klautz1, Jerry Braun1. 1. Department of Cardiothoracic Surgery, Leiden University Medical Centre, Albinusdreef 2, ZA Leiden, The Netherlands. 2. Department of Epidemiology, Leiden University Medical Centre, Albinusdreef 2, ZA Leiden, The Netherlands. 3. Department of Cardiology, Leiden University Medical Centre, Albinusdreef 2, ZA Leiden, The Netherlands.
Abstract
AIMS: Recurrent mitral regurgitation (MR) has been reported after mitral valve repair for functional MR. However, the impact of recurrent MR on long-term survival remains poorly defined. In the present study, mortality-adjusted recurrent MR rates, the clinical impact of recurrent MR and its determinants were studied in patients after mitral valve repair with revascularization for functional MR in the setting of ischaemic heart disease. METHODS AND RESULTS: Long-term clinical and echocardiographic outcome was evaluated in 261 consecutive patients after restrictive mitral annuloplasty and revascularization for moderate to severe functional MR, between 2000 and 2014. The cumulative incidence of recurrent MR ≥ Grade 2, assessed by competing risk analysis, was 9.6 ± 1.8% at 1-year, 20.3 ± 2.5% at 5-year, and 27.6 ± 2.9% at 10-year follow-up. Cumulative survival was 85.8% [95% confidence interval (CI) 81.0-90.0] at 1-year, 67.3% (95% CI 61.1-72.6%) at 5-year, and 46.1% (95% CI 39.4-52.6%) at 10-year follow-up. Age, preoperative New York Heart Association Class III or IV, a history of renal failure, and recurrence of MR expressed as a time-dependent variable [HR 3.28 (1.87-5.75), P < 0.001], were independently associated with an increased mortality risk. Female gender, a history of ST-elevation myocardial infarction, a preoperative QRS duration ≥120 ms, a higher preoperative MR grade, and a higher indexed left ventricular end-systolic volume were independently associated with an increased likelihood of recurrent MR. CONCLUSION: Mitral valve repair for functional ischaemic MR resulted in a low incidence of recurrent MR with favourable clinical outcome up to 10 years after surgery. Presence of recurrent MR at any moment after surgery proved to be independently associated with an increased risk for mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Recurrent mitral regurgitation (MR) has been reported after mitral valve repair for functional MR. However, the impact of recurrent MR on long-term survival remains poorly defined. In the present study, mortality-adjusted recurrent MR rates, the clinical impact of recurrent MR and its determinants were studied in patients after mitral valve repair with revascularization for functional MR in the setting of ischaemic heart disease. METHODS AND RESULTS: Long-term clinical and echocardiographic outcome was evaluated in 261 consecutive patients after restrictive mitral annuloplasty and revascularization for moderate to severe functional MR, between 2000 and 2014. The cumulative incidence of recurrent MR ≥ Grade 2, assessed by competing risk analysis, was 9.6 ± 1.8% at 1-year, 20.3 ± 2.5% at 5-year, and 27.6 ± 2.9% at 10-year follow-up. Cumulative survival was 85.8% [95% confidence interval (CI) 81.0-90.0] at 1-year, 67.3% (95% CI 61.1-72.6%) at 5-year, and 46.1% (95% CI 39.4-52.6%) at 10-year follow-up. Age, preoperative New York Heart Association Class III or IV, a history of renal failure, and recurrence of MR expressed as a time-dependent variable [HR 3.28 (1.87-5.75), P < 0.001], were independently associated with an increased mortality risk. Female gender, a history of ST-elevation myocardial infarction, a preoperative QRS duration ≥120 ms, a higher preoperative MR grade, and a higher indexed left ventricular end-systolic volume were independently associated with an increased likelihood of recurrent MR. CONCLUSION: Mitral valve repair for functional ischaemic MR resulted in a low incidence of recurrent MR with favourable clinical outcome up to 10 years after surgery. Presence of recurrent MR at any moment after surgery proved to be independently associated with an increased risk for mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Zouhair Rahhab; David Scott Lim; Stephen H Little; Maurizio Taramasso; Shingo Kuwata; Matteo Saccocci; Corrado Tamburino; Carmelo Grasso; Christian Frerker; Theresa Wißt; Ross Garberich; Jörg Hausleiter; Daniel Braun; Eleonora Avenatti; Victoria Delgado; Gian Paolo Ussia; Fausto Castriota; Roberto Nerla; Hüseyin Ince; Alper Öner; Rodrigo Estevez-Loureiro; Azeem Latib; Damiano Regazzoli; Nicolo Piazza; Hind Alosaimi; Peter P T de Jaegere; Jeroen Bax; Danny Dvir; Francesco Maisano; Paul Sorajja; Michael J Reardon; Nicolas M Van Mieghem Journal: J Am Heart Assoc Date: 2021-04-02 Impact factor: 5.501
Authors: Andrew J S Coats; Stefan D Anker; Andreas Baumbach; Ottavio Alfieri; Ralph Stephan von Bardeleben; Johann Bauersachs; Jeroen J Bax; Serge Boveda; Jelena Čelutkienė; John G Cleland; Nikolaos Dagres; Thomas Deneke; Dimitrios Farmakis; Gerasimos Filippatos; Jörg Hausleiter; Gerhard Hindricks; Ewa A Jankowska; Mitja Lainscak; Christoph Leclercq; Lars H Lund; Theresa McDonagh; Mandeep R Mehra; Marco Metra; Nathan Mewton; Christian Mueller; Wilfried Mullens; Claudio Muneretto; Jean-Francois Obadia; Piotr Ponikowski; Fabien Praz; Volker Rudolph; Frank Ruschitzka; Alec Vahanian; Stephan Windecker; Jose Luis Zamorano; Thor Edvardsen; Hein Heidbuchel; Petar M Seferovic; Bernard Prendergast Journal: Eur Heart J Date: 2021-03-18 Impact factor: 29.983
Authors: David Messika-Zeitoun; Pascal Candolfi; Maurice Enriquez-Sarano; Ian G Burwash; Vincent Chan; Jean-Francois Philippon; Jean-Manuel Toussaint; Partrick Verta; Ted E Feldman; Bernard Iung; David Glineur; Jean-Francois Obadia; Alec Vahanian; Thierry Mesana Journal: Open Heart Date: 2020-08
Authors: Francesca Ristalli; Silvia Maiani; Brunilda Hamiti; Alessio Mattesini; Francesco Meucci; Miroslava Stolcova; Carlo Di Mario Journal: Front Cardiovasc Med Date: 2019-12-04